DEADLINE ALERT for RCKT, DDD, TEM: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected].
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT )
Class Period: February 27, 2025 – May 26, 2025
Lead Plaintiff Deadline: August 11, 2025
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Rocket knew SAEs, including death of participants enrolled in the study, were a risk; (2) Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
3D Systems Corporation (NYSE: DDD )
Class Period: August 13, 2024 – May 12, 2025
Lead Plaintiff Deadline: August 12, 2025
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Tempus AI, Inc. (NASDAQ: TEM )
Class Period: August 6, 2024 – May 27, 2025
Lead Plaintiff Deadline: August 12, 2025
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; (5) the foregoing issues revealed weakness in core operations and revenue prospects; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Strategy Incorporated (MSTR) Announces Q2 2025 Results
MicroStrategy Incorporated, doing business as, Strategy Incorporated (NASDAQ:MSTR) is one of the Reddit Stocks with the Highest Upside Potential. On July 31, the company announced its Q2 2025 results, with net income coming at $10.0 billion. In Q2 2025 and into July, Strategy Incorporated (NASDAQ:MSTR) delivered another period of strong execution and growth. The company expanded its bitcoin holdings to 628,791 bitcoins, garnered more than $10 billion via its ATM programs and IPOs, and witnessed increased institutional and retail demand for the securities. A software engineer wearing a headset, collaborating with a remote team on a project. Strategy Incorporated (NASDAQ:MSTR)'s operating income for Q2 2025 came in at ~$14.03 billion, a 7,106.4% increase YoY. Operating income consisted of an unrealized gain on the company's digital assets, which amounted to $14.0 billion. Through July 29, the company's Bitcoin holdings make up for 3% of all the Bitcoin ever to be in existence. This places the company as the most dominant player in the Bitcoin Treasury Company space. Strategy Incorporated (NASDAQ:MSTR) raised an impressive $18.3 billion in capital YTD, accounting for 81% of the total capital it raised in all of last year combined. Greenlight Capital, an investment management firm, released its Q4 2024 investor letter. Here is what the fund said: 'There is an open debate as to whether Bitcoin will at some point enter the mainstream as an official currency. In fact, there is a bill before Congress for the U.S. to establish a 'Strategic Bitcoin Reserve' and buy one million Bitcoins over five years. The bill's purpose appears to be the use of public funds to ramp up the price of Bitcoin, thereby enhancing the wealth of existing Bitcoin holders. This seems a dubious use of taxpayer funds, but the new administration has a lot of Bitcoin-owning supporters, so it might happen. More likely, cooler heads will decide that the government should not borrow another trillion dollars in the bond market to speculate in Bitcoin and that there is, in fact, nothing strategic about doing so. While we acknowledge the potential of MSTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Novo Nordisk A/S (NVO) Delivers 18% Sales Growth in H1 2025
Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated that it delivered 18% sales growth in H1 2025. The company has lowered its full-year outlook because of lower growth expectations for its GLP-1 treatments in H2 2025. Therefore, it has been taking measures to sharpen its commercial execution further, and ensure efficiencies in its cost base while continuing to make investments in future growth. With over 1 billion people living with obesity globally, which includes over 100 million living in the US, and only a few million on treatment, Novo Nordisk A/S (NYSE:NVO) expects to maximise the strong growth opportunities, thanks to the healthy product portfolio and future pipeline. A closeup shot of a laboratory technician handling a medical device used for fertility treatments. Novo Nordisk A/S (NYSE:NVO) highlighted that the sales within Diabetes and Obesity care rose 16% in Danish kroner to DKK 145.4 billion (and 18% at CER), mainly due to the Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (and 58% at CER) and GLP-1 diabetes sales increasing 8% in Danish kroner (10% at CER). Within R&D, Novo Nordisk A/S (NYSE:NVO) plans to advance subcutaneous and oral amycretin into phase 3 development in weight management on the basis of completed clinical studies during Q1 2025. For FY 2025, the sales growth is anticipated to be 8% – 14% at CER, and operating profit growth is projected to be 10% – 16% at CER. ClearBridge Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a new position in Novo Nordisk A/S (NYSE:NVO), the global leader in diabetes care and one of two dominant players in the fast-growing GLP-1 diabetes and obesity drug market. A slowdown in prescriptions for Novo's GLP-1 drugs, combined with confusion surrounding a clinical trial of its next-generation candidate, CagriSema, caused a significant pullback in the stock. We saw this as a buying opportunity. We believe the GLP-1 market remains vast and that Novo (alongside Eli Lilly) is well-positioned to maintain a duopolistic structure for years to come, given the complexity of manufacturing, differentiated intellectual property and brand strength. We also expect growth to reaccelerate as supply ramps up following its acquisition of Catalent and as regulators crack down on unlicensed compounders.' While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Bank of America Securities Reiterates Buy Rating on Crocs (CROX) Stock
Crocs, Inc. (NASDAQ:CROX) is one of the Reddit Stocks with the Highest Upside Potential. On August 8, Bank of America Securities analyst Christopher Nardone reiterated a 'Buy' rating on the company's stock and set a price objective of $99.00. The analyst's rating is backed by a combination of factors demonstrating potential for future growth amidst the current challenges. As per the analyst, while Q3 2025 guidance was disappointing, there remains an optimistic outlook for Crocs, Inc. (NASDAQ:CROX)'s fundamentals to witness improvement beyond this period. A busy retail store full of customers trying on a wide range of footwear. Furthermore, the international segment demonstrated a promising growth in Q2 2025, and the analyst opines that a low double-digit growth rate remains achievable in the upcoming quarters. Even though there are short-term pressures due to the tariffs and changes in product mix, the analyst opines that the gross margin is expected to stay strong because of Crocs, Inc. (NASDAQ:CROX)'s emphasis on controlling promotions. This strategic approach is expected to support a healthy FCF profile, added Nardone. While North American sales are projected to encounter challenges, the analyst anticipates gradual improvement on the back of new product innovations as well as strategic adjustments to offset tariff impacts. Artisan Partners, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'Among our top detractors were Halozyme, Crocs, Inc. (NASDAQ:CROX) and Novanta. Crocs designs, develops, manufactures and distributes casual footwear and accessories for men, women and children. The company invented the molded plastic clog in 2002 and turned it into a multibillion-dollar (USD) global revenue producer. We believe expansion opportunities outside the US, demand from new product introductions (including from recently acquired Hey Dude) and distribution pushes within the direct-to-consumer and wholesale channels will drive greater-than-expected revenue growth. We had expected the performance of its HeyDude brand to have already bottomed, but forward guidance continues to indicate its turnaround efforts, driven by a new divisional leader, will take longer than expected. We maintained our position as we believe the market underappreciates the longer term profit cycle.' While we acknowledge the potential of CROX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
